Sixty nine patients with non-ulcer dyspepsia have been studied with endoscopy, biopsy, quick urease (CLO) test, Helicobacter pylori culture, and the 13C-urea breath test before and after treatment with tripotassium dicitratobismuthane (DeNol) two tablets twice daily for four weeks. Symptoms of non-ulcer dyspepsia were recorded using a standard questionnaire. Using H pylori culture as the gold standard, the sensitivity of the 13C-urea breath test was 90%, the specificity 98.6%, and the accuracy 94.8% with a positive predictive value of 98.2% and a negative predictive value of 92.5%. Conversion rate from H pylori positive to negative status after treatment with tripotassium dicitratobismuthate was 17.9%. Symptoms of non-ulcer dyspepsia improved appreciably after treatment irrespective of H pylori status. The 13C-urea breath test is an accurate research tool suitable for serial testing and population surveys.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1378691PMC
http://dx.doi.org/10.1136/gut.31.11.1237DOI Listing

Publication Analysis

Top Keywords

13c-urea breath
16
breath test
16
non-ulcer dyspepsia
16
helicobacter pylori
8
tripotassium dicitratobismuthate
8
pylori culture
8
treatment tripotassium
8
symptoms non-ulcer
8
test
5
pylori
5

Similar Publications

Introduction: Previous studies reported inconsistent results of the association between Helicobacter pylori infection and nonalcoholic fatty liver disease (NAFLD).

Methods: A cohort study of 2,063 adults without NAFLD at baseline, who participated in a repeated health checkup including a 13C-urea breath test and abdominal ultrasonography, was conducted to evaluate the link between H. pylori infection and NAFLD development.

View Article and Find Full Text PDF
Article Synopsis
  • Vonoprazan (VPZ) shows better acid-inhibition than proton pump inhibitors (PPIs) but little research has been done on its effectiveness in treating Helicobacter pylori infection with bismuth quadruple therapy (VBQT).* -
  • This study evaluated VBQT's safety and effectiveness in eradicating H pylori in treatment-naive patients over a period from March 2021 to May 2023, involving 612 participants.* -
  • Results indicated high eradication rates of 84.3% to 96.4% across various analyses, with a 12.7% adverse event rate and 96.9% treatment compliance, suggesting VBQT is a promising first-line treatment for
View Article and Find Full Text PDF

Objectives: We started () screening program of students at Juntendo university in 2020. We report the current status of screening program and the outcomes of screening program.

Methods: The students of the School of the Faculty of Health Sciences of Juntendo University enrolling in the spring of 2020-2022 were recruited for this study.

View Article and Find Full Text PDF

Background: The global prevalence of obesity is increasing and represents a major public health challenge. However, there is a paucity of data regarding Helicobacter pylori (H pylori) eradication in people with obesity. The aim of the study is to examine the influence of obesity degree on H.

View Article and Find Full Text PDF

Background: Due to lower operational costs, health maintenance organizations (HMOs) may prioritize stool antigen testing (HpStAg) for the non-invasive diagnosis of infection over 13C-urea breath tests (13C-UBTs). The aim of our study was to compare the accuracy of the diagnostic tests for .

Methods: We performed histology, rapid urease test (RUT), 13C-UBT and HpStAg on consecutive patients referred for gastroscopy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!